News

: AstraZeneca CEO’s pay package contested by investors

0

The Investment Association, an influential investors group from the City of London, has come out against the proposed annual pay package of AstraZeneca
AZN,
+0.62%

AZN,
-0.18%

Chief Executive Pascal Soriot, which could potentially net him some £18 billion ($25 million).

  • The move from the U.K. asset managers’ trade body comes on the eve of the pharmaceuticals group’s annual meeting on Tuesday, where investors will have to approve a hefty raise of Soriot’s bonus for this year.
  • The Investment Association issued its “amber warning” on the compensation scheme, its second-highest level of alert, according to the Times of London.
  • Three other investors advisory groups had already advised voting against the package, which would increase the French-born CEO’s annual salary by 3% to £1.3 million, and bump his share award to a maximum of 650 percent that amount, with his annual bonus raising to a potential 250% of his salary.
  • According to the AstraZeneca annual report, the package would be worth £17.8 million if the company’s share price raises by 50%, and £8.6 million if the stock doesn’t rise.

Read: Under-40s to be offered alternative COVID-19 vaccines to AstraZeneca’s in the U.K.

: The U.S. prepares to begin giving COVID-19 shots to 12- to 15-year-olds as Pfizer’s vaccine nears expanded authorization

Previous article

: Box activism battle heats up as Starboard nominates four director candidates

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News